Session » Miscellaneous Rheumatic and Inflammatory Diseases I
- 2:30PM-4:00PM
-
Abstract Number: 939
Long-Term Efficacy and Safety of Canakinumab in Active Hyperimmunoglobulinemia D with Periodic Fever Syndrome
- 2:30PM-4:00PM
-
Abstract Number: 938
Long-Term Efficacy and Safety of Canakinumab in Patients with Active Recurrent or Chronic TNF Receptor-Associated Periodic Syndrome
- 2:30PM-4:00PM
-
Abstract Number: 940
NOD2-Associated Autoinflammatory Disease: Therapy and Outcomes
- 2:30PM-4:00PM
-
Abstract Number: 941
Relationship Between Colchine Plasma Level and Frequency of Familial Mediterranean Fever Attacks
- 2:30PM-4:00PM
-
Abstract Number: 937
Safety and Efficacy of Canakinumab in Patients with CAPS: Interim Results from the Beta-Confident Registry
- 2:30PM-4:00PM
-
Abstract Number: 942
Update in the Management of Biologic Response Modifiers and Disease-Modifying Antirheumatic Drugs Following Coccidioidomycosis